SUBSCRIBE
SUBSCRIBE

Kite Pharma

NEWS
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Policy
Onco-Immunology Companies like Juno, Novartis AG, Kite Pharma Struggle to Mass Produce Custom Cancer Therapies
October 30, 2015
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
SoCal’s Kite Pharma Strikes Cancer Deal Worth $535 Million+ with Alpine Immune Sciences
October 27, 2015
 · 
3 min read
Genetown
Why Kite Pharma Needs To Shut Its Big Mouth
August 18, 2015
 · 
1 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
Kite Pharma CEO Refutes Rumors of Death Associated with Experimental Cancer Drug
August 17, 2015
 · 
2 min read
Biowarfare Company Emergent's Cancer Spinoff Aptevo Therapeutics to Employ 70 - 90 in Seattle
Job Trends
Kite Pharma Breaks Ground on New Facility in SoCal That Will Create 200 New Jobs
August 7, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Partnership and Acquisition Rumors in the CAR-T Cancer Space Finger Juno, Kite Pharma and bluebird bio
July 16, 2015
 · 
4 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Kite Pharma, bluebird bio Ink Deal to Zero In on HPV-Linked Cancer
June 22, 2015
 · 
4 min read
EXCLUSIVE: New Report Says Biosimilars Will Earn $55B by 2020, As Pfizer, Actavis, Abbvie Claim U.S. Market
Biotech Beach
Kite Pharma CEO Avoids Big Tax Bite By Exercising Options Before IPO
May 4, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Drug Development
CAR-T Cell Companies Juno Therapeutics, Kite Pharma, and ZIOPHARM, Inc. Get Stock Jitters on Disappointing Novartis AG Trial News
April 21, 2015
 · 
2 min read
Load More
AWARDS
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Press Releases
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
December 8, 2025
 · 
19 min read
Press Releases
Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
December 8, 2025
 · 
6 min read
Press Releases
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma
December 8, 2025
 · 
10 min read
Press Releases
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
November 3, 2025
 · 
19 min read
Press Releases
Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025
June 2, 2025
 · 
17 min read
Press Releases
Gilead and Kite Announce Presentation of Transformative Data in 1L Metastatic Triple-Negative Breast Cancer, Updated Results in Multiple Myeloma and Early Data From Novel Investigational CAR T-Cell Therapy Targeting Brain Cancer at 2025 ASCO and EHA
May 15, 2025
 · 
19 min read
Press Releases
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
December 10, 2024
 · 
19 min read
Press Releases
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
December 10, 2024
 · 
18 min read
Press Releases
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
December 9, 2024
 · 
19 min read
Biotech Bay
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
May 9, 2024
 · 
9 min read
Load More